NanoViricides, Inc. · AMEX:NNVC
NanoViricides — Investor Presentation (February 2020)
27 slides from NanoViricides's investor presentation, Feb 24, 2020
Slide 1: Corporate Presentation: Bind-Encapsulate-Destroy
“Bind-Encapsulate-Destroy” NNVC (NYSE American) NanoViricides’ Topical Drug Candidate Against Shingles (VZV) Preparing for Regulatory Trials; SARS-CoronaVirus-2 Therapeutics in Development An Array of Indications in Herpecide™ Program Alone Corporate Presentation February 24, 2020 Presented by: Anil
Slide 2: Disclosure Statement
Disclosure Statement NanoViricides, Inc. is a NYSE-American listed publicly traded company (stock symbol: NNVC). This is not an offering memorandum and should not be construed as such. It is provided as a non-confidential document for informational purposes only. NanoViricides, Inc.(www.nanoviricide
Slide 3: Presentation Layout
Presentation Layout Developing Drugs that Virus May Not Escape due to Mutations Industry-Leading Platform Technology Exclusively Licensed from TheraCour Pharma, Inc. Our Own cGMP-Capable Manufacturing, R&D, and Nanomedicine Characterization Facility Enables Rapid Development and Potential for Early
Slide 4: Presentation Layout
Developing Drugs that Virus May Not Presentation Escape due to Mutations Layout Our Own cGMP-Capable Manufacturing, R&D, and Nanomedicine Characterization Facility Enables Rapid Development and Potential for Early Commercialization Revenues On Our Own Broad Pipeline with Multi-Billion Dollar Markets
Slide 5: Novel Platform Technology: A nanoviricide is a Cell Mimic
Novel Platform Technology: A nanoviricide® is a Cell Mimic Viral Resistance to the Nanoviricide Drug is Unlikely because Even as the Virus Mutates, It Still Binds to the Same Cell Surface Receptor(s), in the Same Fashion HIV Particle binding to a Cell via CD4 and a Coreceptor ® CD4 “Key” that binds
Slide 6: A NanoViricide Attacking a Virus Particle
A NanoViricide® Attacking a Virus Particle: Unique, Novel, Nanotech Design ENCAPSULATE DESTROY BIND © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-mkt: NNVC) Slide 6
Slide 7: Nanoviricides Dismantling MCMV Virus Particle
Nanoviricides Dismantling MCMV Virus Particle Control Treated A MCMV Virus Particle Containing Multiple Capsids Virus Dismantled; Capsids Spilling Out A: intermediate state; C: total dismantling C © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-mkt: NNVC) © All Rights Res
Slide 8: Unique Drug Developer with Own cGMP-Capable Manufacturing
NanoViricides is a Unique Drug Developer Company with Its Own cGMP-Capable Manufacturing Capability Clinical Product Supply Capability for Mostly All of Our Nanoviricides Significant Time and Cost Savings Potential for Manufacturing Commercial Product - Market Entry & Early Revenues Nanomedicines Ch
Slide 9: Platform Technology Has Enabled Several Drug Programs
NanoViricides Platform Technology Has Enabled Several Drug Programs for a Broad Drug Pipeline Pre-Clinical Successes Achieved in Several Programs FluCide™ FluCide™ HivCide™ DengueCide™ SARS-CoV-2 a. Injectable b. Oral “Functional Cure?” Avoid ADE For Hospitalized For Out-Patients West Nile Virus, Pa
Slide 10: SARS-CoV-2 NanoViricide Drug Development Using Biomimetic Technology
SARS-Cov-2 NanoViricide Drug Development Using Biomimetic Technology NanoViricides Has Already Designed Multiple Small Chemical Ligands to Mimic ACE-2 Epitope at which SARS-Cov S1 Binds Angiotensin Converting Enzyme 2 (ACE2) Serves as Receptror for the 2002 SARS- CoV as well as the 2019 SARS-CoV-2 B
Slide 11: Leveraging Herpecide Program into Multiple Drugs Franchise
The patient reported a history of right-sided herpes zoster Our Current Focus is on the HerpeCide™ Program Regulatory Development underwent anterior cham ophthalmicus 1 month prior for which she completed a merase chain reaction an 10 day course of famciclovir. Past medical history included chicken
Slide 12: NanoViricides' Regulatory Strategy
NanoViricides’ Regulatory Strategy Dermal Topical Drug as First Candidate -> Quicker Path rather than systemic therapeutics Multiple Indications with Same Drug Candidate or its Derivatives to Maximize Shareholder Value and ROI Distribute Development Costs over Multiple Indications VZV Shingles Herpe
Slide 13: Lead Drug Candidate NV-HHV-101: Business Case
Lead Drug Candidate NV-HHV-101: Business Case Potentially Billion+ Dollar Market for Topical Shingles Rash Treatment alone, even after the new vaccine Shingrix® has been introduced 500,000 to 1,000,000 Cases Annually in the USA Alone Additionally, NV-HHV-101 is Expected to Lead into Dermal Topical T
Slide 14: NV-HHV-101 Status - Getting Ready for IND Filing
Lead Drug Candidate NV-HHV-101 Status - Getting Ready for IND Filing Indication: Shingles Rash Treatment. Form: Topical Skin Cream Anticipate Human Clinical Trials to Begin in CY 2020 Q1/Q2 FDA Response “Generally Adequate” on Pre-IND Filed with FDA Non-Clinical Safety/Toxicology Studies Complete -
Slide 15: Investment Thesis: Platform Technology and Facility
Investment Thesis: NanoViricides Platform Technology and Facility Platform Technology - A “Venus-Fly-Trap” for Viruses - “Bind-Encapsulate-Destroy” - Drugs that Viruses Cannot Escape by Mutations Multiple Drug Programs with Many Candidates having demonstrated Successful Animal Model Effectiveness an
Slide 16: Investment Thesis: NanoViricides Valuation
Investment Thesis: NanoViricides Valuation Company Founded and taken public (reverse shell merger) in 2005 - Platform Technologies Licensed from TheraCour Pharma, Inc. Market Cap Historically Around $100~150M Uplisted to NYSE-American in September 2013 Moved to Integrated cGMP Manufacturing & R&D Fa
Slide 17: Shingles Rash Breakouts - HHV-3 aka VZV
Shingles Rash breakouts - HHV-3 aka VZV Unmet Medical Need : Available drugs in use not very effective (vaccines exist) The chickenpox virus surviving in ganglia causes Shingles in adults About 500,000 to 1 Million Cases Per Year in the USA Alone Risk Increases with Age Triggered by Reduced Immune F
Slide 18: Lead Drug Candidate NV-HHV-101 Dermal Topical Skin Cream
Lead Drug Candidate NV-HHV-101 Dermal Topical Skin Cream for Treating Shingles Rash Risk is Minimized for Human Clinical Studies, Since Efficacy and Safety Data are Obtained in Human Skin Itself Standard of Care, Valtrex® Oral, is Not Very Effective Because viral TK enzyme activity required for conv
Slide 19: VZV Topical Candidates Five Times More Effective than Acyclovir
Optimization Studies VZV (Shingles) Topical Candidates Highly Effective - Five Times More Effective against VZV than Acyclovir in Cell Cultures (Pre-Clinical) NanoViricides Drug Candidates Effective Against VZV (Shingles Virus) Infection 125 Virus Production at 6 days in cell culture, by GP1-ELISA,
Slide 20: Match Efficacy of Cidofovir in Human Skin Organ Culture Model
VZV (Shingles) Topical Drug Candidates Are Highly Effective Match Efficacy of Cidofovir in Human Skin Organ Culture Model of VZV Infection (Pre-Clinical) NV-118 Treated VZV Infected Skin Normal Dermis and Epidermis. No viral infiltration or lesions seen VZV Infected Skin - Basal Layer Breaches seen,
Slide 21: VZV Topical Candidate Moving Rapidly To Clinical Trials
VZV (Shingles) Topical Candidate Moving Rapidly To Clinical Trials Preliminary Non-GLP Safety/Tolerability Studies in Rats Successful (2018) No clinically observable adverse safety and toxicology effects in topical administration No clinically observable adverse safety and toxicology effects in syst
Slide 22: IND-Enabling Safety/Toxicology Package Studies
VZV (Shingles) Topical Drug Candidate : IND-Enabling Safety/Toxicology Package Studies Non-GLP Studies Non-GLP Portion of IND-Enabling Safety/Toxicology Studies Completed by BASi, IN ca. February, 2019 Excellent Safety Profile Observed cGMP Manufacture for GLP Safety/Toxicology Studies Completed GLP
Slide 23: HerpeCide Program Future Expansion
HerpeCide™ Program Future Expansion Drug Candidates in Current HerpeCide Program May Have Applications Against Other HerpesViruses: Epstein-Barr Virus: Mononucleosis Monoclonal Gammopathy other B-cell diseases, etc. Cytomegalovirus: Retinitis, Organ Transplant etc. HHV-6A, HHV-6B, HHV-7 several dise
Slide 24: Strong Executive Team
Strong Executive Team Anil R. Diwan, PhD Randall W. Barton, PhD President & Exec. Chairman CSO and Acting CRO Co-Founder 30+ Years of Pharmaceutical Industry Experience in Drug Led Uplisting to NYSE-American Exchange in 2013 Discovery and Pre-clinical Regulatory Development Raised $65M Former Direct
Slide 25: Board of Directors
Board of Directors Anil R. Diwan, PhD Stanley Glick, CPA ✔ President & Exec. Chairman Chairman, Audit Committee Co-Founder, Led Uplisting to NYSE-Amer. in 2013, Raised $65M+, Co-Inventor of Nanoviricides® & of TheraCour ® Auditing, Accounting, Tax, & Mgmt. Advisory Services 25+ years Leadership & En
Slide 26: Recap
Recap “Resistance is Futile” - Antiviral Nanomachines Designed to Destroy Viruses Despite Viral Mutations Broad and Deep Pipeline based on Platform Technology In-house cGMP Manufacture Enabling Early Commercial Revenues On Its Own Major Regulatory Progress and Milestones to Occur Throughout Next Sev
Slide 27: The End
The End © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-Amer.: NNVC) Slide 27
NanoViricides — Investor Presentation (February 2020) on 6ix